Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jun;84(12):1624–1629. doi: 10.1054/bjoc.2001.1847

Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients

D D Taylor 1, D P Bender 1, Ç Gerçel-Taylor 1, J Stanson 2, T L Whiteside 2
PMCID: PMC2363678  PMID: 11401315

Abstract

In women with ovarian cancer, suppression of components of the immune system may promote tumour development. Previous studies in ovarian cancer have demonstrated that decreased expression and function of the T-cell receptor (TcR)-associated signal transducing zeta-chain correlates with deficient immune responsiveness of T cells. In this study, sera and ascitic fluids obtained from woman with advanced ovarian cancer were found to suppress the expression of TcR-associated zeta chain. This suppression of zeta chain expression was dose-dependent and was not observed with biologic fluids obtained from healthy women. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: TcR/CD3-zeta, immunosuppression, ovarian cancer

Full Text

The Full Text of this article is available as a PDF (138.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Knapp R. C. Immunologic approaches to the management of ovarian carcinoma. Semin Oncol. 1984 Sep;11(3):264–274. [PubMed] [Google Scholar]
  2. Braun D. P., Harris J. E. Serial immune function testing to predict clinical disease relapse in patients with solid tumors. Cancer Immunol Immunother. 1983;15(3):165–171. doi: 10.1007/BF00199159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brooks B., Rees R. C. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity. Clin Exp Immunol. 1988 Nov;74(2):162–165. [PMC free article] [PubMed] [Google Scholar]
  4. Brown R., Clugston C., Burns P., Edlin A., Vasey P., Vojtesek B., Kaye S. B. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer. 1993 Oct 21;55(4):678–684. doi: 10.1002/ijc.2910550428. [DOI] [PubMed] [Google Scholar]
  5. Chan A. C., Desai D. M., Weiss A. The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu Rev Immunol. 1994;12:555–592. doi: 10.1146/annurev.iy.12.040194.003011. [DOI] [PubMed] [Google Scholar]
  6. Irving B. A., Chan A. C., Weiss A. Functional characterization of a signal transducing motif present in the T cell antigen receptor zeta chain. J Exp Med. 1993 Apr 1;177(4):1093–1103. doi: 10.1084/jem.177.4.1093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kersh E. N., Kersh G. J., Allen P. M. Partially phosphorylated T cell receptor zeta molecules can inhibit T cell activation. J Exp Med. 1999 Dec 6;190(11):1627–1636. doi: 10.1084/jem.190.11.1627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kuss I., Saito T., Johnson J. T., Whiteside T. L. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res. 1999 Feb;5(2):329–334. [PubMed] [Google Scholar]
  9. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  10. Lai P., Rabinowich H., Crowley-Nowick P. A., Bell M. C., Mantovani G., Whiteside T. L. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res. 1996 Jan;2(1):161–173. [PubMed] [Google Scholar]
  11. Liossis S. N., Ding X. Z., Dennis G. J., Tsokos G. C. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest. 1998 Apr 1;101(7):1448–1457. doi: 10.1172/JCI1457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Maccalli C., Pisarra P., Vegetti C., Sensi M., Parmiani G., Anichini A. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. J Immunol. 1999 Dec 15;163(12):6912–6923. [PubMed] [Google Scholar]
  13. Mulder W. M., Bloemena E., Stukart M. J., Kummer J. A., Wagstaff J., Scheper R. J. T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut. 1997 Jan;40(1):113–119. doi: 10.1136/gut.40.1.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Old L. J. Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res. 1981 Feb;41(2):361–375. [PubMed] [Google Scholar]
  15. Rabinowich H., Reichert T. E., Kashii Y., Gastman B. R., Bell M. C., Whiteside T. L. Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest. 1998 Jun 1;101(11):2579–2588. doi: 10.1172/JCI1518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rabinowich H., Suminami Y., Reichert T. E., Crowley-Nowick P., Bell M., Edwards R., Whiteside T. L. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer. 1996 Nov 4;68(3):276–284. doi: 10.1002/(SICI)1097-0215(19961104)68:3<276::AID-IJC2>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  17. Reichert T. E., Rabinowich H., Johnson J. T., Whiteside T. L. Mechanisms responsible for signaling and functional defects. J Immunother. 1998 Jul;21(4):295–306. doi: 10.1097/00002371-199807000-00007. [DOI] [PubMed] [Google Scholar]
  18. Shores E. W., Tran T., Grinberg A., Sommers C. L., Shen H., Love P. E. Role of the multiple T cell receptor (TCR)-zeta chain signaling motifs in selection of the T cell repertoire. J Exp Med. 1997 Mar 3;185(5):893–900. doi: 10.1084/jem.185.5.893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Suminami Y., Elder E. M., Lotze M. T., Whiteside T. L. In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother Emphasis Tumor Immunol. 1995 May;17(4):238–248. doi: 10.1097/00002371-199505000-00006. [DOI] [PubMed] [Google Scholar]
  20. Tartour E., Latour S., Mathiot C., Thiounn N., Mosseri V., Joyeux I., D'Enghien C. D., Lee R., Debre B., Fridman W. H. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer. 1995 Oct 9;63(2):205–212. doi: 10.1002/ijc.2910630210. [DOI] [PubMed] [Google Scholar]
  21. Yasumura S., Amoscato A., Hirabayashi H., Lin W. C., Whiteside T. L. Proliferation of hematopoietic cell lines induced by a soluble factor derived from human squamous cell carcinomas of the head and neck. Cancer Immunol Immunother. 1994 Dec;39(6):407–415. doi: 10.1007/BF01534429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Zea A. H., Curti B. D., Longo D. L., Alvord W. G., Strobl S. L., Mizoguchi H., Creekmore S. P., O'Shea J. J., Powers G. C., Urba W. J. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res. 1995 Nov;1(11):1327–1335. [PubMed] [Google Scholar]
  23. de Gruijl T. D., Bontkes H. J., Peccatori F., Gallee M. P., Helmerhorst T. J., Verheijen R. H., Aarbiou J., Mulder W. M., Walboomers J. M., Meijer C. J. Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes. Br J Cancer. 1999 Mar;79(7-8):1127–1132. doi: 10.1038/sj.bjc.6690179. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES